Clinical trials: Psoriasis; Plaque
Plaque Psoriasis, Psoriasis
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
Study to evaluate the efficacy and safety of JTE-451 administered for 16 weeks in subjects with moderate to severe plaque psoriasis.
- Conditions
- Plaque Psoriasis, Psoriasis, Skin Diseases
- Trial name
- IMPACT-PS (NCT03832738)
- Testing
- JTE-451 Tablets
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 152 people
- Sponsor
- Shionogi Inc.
Moderate to Severe Plaque Psoriasis
Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis
This study is a randomized, double-blind, placebo-controlled, multicenter clinical trial of about 70 subjects with moderate to severe plaque psoriasis.
- Trial name
- NCT05342428
- Testing
- TLL018 tablets
- Where
- China
- Volunteers
- 73 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Plaque Psoriasis
A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis
This is a study of itacitinib in patients with chronic plaque psoriasis. This study will evaluate safety and efficacy parameters of itacitinib.
- Trial name
- NCT01634087
- Testing
- Itacitinib
- Where
- 9 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Incyte Corporation
Plaque Psoriasis
Study Evaluation of the Efficacy, Safety and Immunogenicity of Adalimumab in Comparison With Humira®
MABPS-3/2020 is a double-blind randomized multicenter clinical trial comparing efficacy, immunogenicity and safety profiles of Adalimumab (manufactured by Mabscale, LLC) compared to Humira®.
- Trial name
- NCT06005532
- Testing
- Adalimumab, Humira
- Where
- 9 sites in Russia
- Volunteers
- 494 people
- Sponsor
- Mabscale, LLC
Psoriasis
A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe Psoriasis
This is a randomized, double-blind, placebo-controlled, multi-center Phase II clinical study to evaluate the efficacy and safety of AK111 for the treatment of moderate to severe plaque psoriasis.
- Trial name
- NCT05096364
- Where
- 13 sites in China
- Volunteers
- 251 people
- Sponsor
- Akeso
Psoriasis
Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque Psoriasis
To estimate the difference in effectiveness between treatment with etanercept 50 mg twice weekly (BIW) and treatment with etanercept 50 mg once weekly (QW) plus an as needed (PRN) topical agent for 12 weeks in adults with…
- Trial name
- REFINE (NCT01313221)
- Testing
- etanercept, Topical agents
- Where
- 24 sites in Canada
- Volunteers
- 310 people
- Sponsor
- Amgen
Psoriasis
Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants.
This study was designed to prove and quantify the hypothesis that secukinumab is effective, safe and well tolerated in the treatment of moderate to severe chronic plaque-type psoriasis in patients who are inadequate responders to…
- Trial name
- SIGNATURE (NCT01961609)
- Testing
- Secukinumab (AIN457)
- Where
- 54 sites in Ireland, United Kingdom
- Volunteers
- 235 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis
A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Plaque Psoriasis
- Trial name
- NCT04908514
- Testing
- ADX-629
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Psoriasis
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
The purpose of the study is to evaluate the efficacy, safety, pharmacokinetics, immunogenicity, usability, and acceptability of guselkumab delivered using SelfDose device in participants with moderate to severe plaque-type…
- Trial name
- NCT02905331
- Testing
- Guselkumab
- Where
- 14 sites in United States, Canada and 1 more
- Volunteers
- 78 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis, Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)
The purpose of this study is to investigate the efficacy and safety of two dose levels of certolizumab pegol in adults with moderate to severe chronic plaque psoriasis.
- Trial name
- CIMPASI-2 (NCT02326272)
- Testing
- Certolizumab Pegol
- Where
- 23 sites in United States, Austria and 2 more
- Volunteers
- 227 people
- Sponsor
- UCB Biopharma S.P.R.L.
Active Plaque Psoriasis
Study to Assess VB-201 in Patients With Psoriasis
The purpose of this study is to examine the efficacy, safety and tolerability of VB-201 as compared with placebo on measures of disease activity in patients with psoriasis.
- Trial name
- NCT01001468
- Testing
- VB-201
- Where
- 18 sites in United States, Germany and 1 more
- Volunteers
- 185 people
- Sponsor
- Vascular Biogenics Ltd. operating as VBL Therapeutics
Plaque-type Psoriasis
Safety Study of Ointment for the Treatment of Plaque-type Psoriasis
The purpose of this study is to determine how much drug is absorbed throughout the body after being applied to the skin.
- Trial name
- AN2728-PSR-104 (NCT01258088)
- Testing
- AN2728 Ointment, AN2728 Vehicle
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Psoriasis
Evaluate the Efficacy and Safety of M518101 in Subjects With Plaque Psoriasis
This study is to evaluate the efficacy and safety of M518101 in subjects with plaque psoriasis
- Trial name
- NCT01878461
- Testing
- Vehicle, M518101
- Where
- 34 sites in United States
- Volunteers
- 542 people
- Sponsor
- Maruho North America Inc.
Psoriasis
Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
Safety and Efficacy of IDP-118 Lotion in the Treatment of Plaque Psoriasis
- Trial name
- NCT02785159
- Testing
- IDP-118 Lotion, Tazorac Cream, IDP-118 Vehicle Lotion
- Where
- 14 sites in United States
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Plaque Psoriasis
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis
The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: Does ESK-001 reduce the severity of people's psoriasis? How safe is ESK-001 in…
- Trial name
- ONWARD1 (NCT06586112)
- Testing
- Envudeucitinib, Apremilast
- Where
- 156 sites in United States, Australia and 8 more
- Volunteers
- 912 people
- Sponsor
- Alumis Inc
Psoriasis
A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis
The purpose of this study is to evaluate the efficacy (good or bad effects) and safety of ustekinumab in the treatment of patients with moderate to severe psoriasis in China.
- Trial name
- NCT01008995
- Testing
- ustekinumab
- Where
- 9 sites in China
- Volunteers
- 322 people
- Sponsor
- Centocor, Inc.
Psoriasis
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.
- Trial name
- POETYK-PSO-2 (NCT03611751)
- Testing
- BMS-986165, Apremilast
- Where
- 205 sites in United States, Australia and 14 more
- Volunteers
- 1,020 people
- Sponsor
- Bristol-Myers Squibb
Chronic Plaque Psoriasis
TRUST Study: Raptiva ® in Hand & Foot Psoriasis
To evaluate the safety and efficacy of Raptiva ® compared with placebo to control chronic moderate to severe plaque psoriasis involving the hands and/or feet scoring Physician's Global Assessment (PGA - H\&F) greater-than or…
- Trial name
- TRUST (NCT00739882)
- Testing
- Efalizumab - anti CD11a recombinant human monoclonal antibody
- Where
- Austria
- Volunteers
- 76 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Hidradenitis Suppurativa, Pediatric Plaque Psoriasis
Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Regulatory Post-Marketing Surveillance in hidradenitis suppurativa, pediatric plaque psoriasis and JIA treated with Cosentyx®(secukinumab) in Korea
- Conditions
- Hidradenitis Suppurativa, Pediatric Plaque Psoriasis, Juvenile Idiopathic Arthritis
- Trial name
- NCT07243782
- Testing
- Secukinumab
- Where
- South Korea
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Plaque Psoriasis
A Study to Assess the Efficacy and Safety of Alefacept in Psoriasis Patients for Whom Conventional Treatment is Ineffective or Inappropriate
To assess the efficacy and safety of Alefacept compared to placebo for the treatment of Chronic Plaque Psoriasis in patients for whom conventional therapies are ineffective and inappropriate
- Trial name
- NCT00673556
- Testing
- alefacept
- Where
- 34 sites in United States, Austria and 3 more
- Volunteers
- 195 people
- Sponsor
- Astellas Pharma Inc